study question: Are brain-derived neurotrophic factor (BDNF) and its receptors, NTRK2, NGFR and SORT1, regulated by ovarian steroids in the uterus? summary answer: BDNF and its low affinity receptor, nerve growth factor receptor (NGFR), are regulated by estradiol in the uterus. what is known already: Recent studies have revealed a central role for neurotrophins in placental development, endometrial stem cell neurogenesis, endometrial carcinoma and endometriosis. Complex signaling pathways involving BDNF and its receptors are regulated by ovarian hormones in the brain, however their expression and regulation in the uterus is poorly defined. study design, size, duration: This experimental animal study involved a total of 80 mice. participants/materials, setting, methods: Female C57BL/6 mice (n ¼ 50) were monitored daily for estrous cycle stage, and uterine horns were collected. A second group of mice (n ¼ 30) were ovariectomized and given estradiol, progesterone, estradiol + progesterone, or saline for 4 days. Uterine expression of BDNF and its receptors were quantified by real-time PCR and western blot, and localized using immunohistochemistry.
Introduction
Although mainly recognized for their supportive function within the nervous system, brain-derived neurotrophic factor (BDNF) and its high affinity receptor neurotrophic tyrosine receptor kinase 2 (NTRK2) have been shown to participate in ovarian development (Dorfman et al., 2011) , follicular development (Kerr et al., 2009) and oocyte survival (Dorfman et al., 2014) . The neurotrophins are also important in endometrial physiology where they participate in endometrial stem cell neurogenesis (Shoae-Hassani et al., 2011) and normal placental development (Kawamura et al., 2009 (Kawamura et al., , 2011 Non et al., 2012) . However, the overexpression of neurotrophins is associated with reproductive pathologies including premature ovarian failure (Dorfman et al., 2014) , endometrial cancer (Bao et al. 2013 ) and endometriosis (Borghese et al., 2010; Browne et al., 2012; Barcena de Arellano et al., 2013) .
The neurotrophins are small molecular weight proteins that act in the nervous system to promote neuronal development, differentiation, growth and maintenance (reviewed in Chao, 2003) . The neurotrophin signaling network is complex. Neurotrophins can be translated as proproteins and cleaved into their active forms (Mowla et al., 2001, Gray and Ellis, 2008) or they can induce signaling cascades in their pro-forms (Lee et al., 2001; Koshimizu et al., 2009) . Generally, the two forms have opposing functions (reviewed in Chao and Bothwell, 2002; Teng et al. 2010) . The neurotrophin family comprises four ligands, BDNF, nerve growth factor (NGF), neurotrophin 3 (NTF3) and neurotrophin 4 (NTF4), and four receptors: neurotrophic tyrosine receptor kinase (NTRK) 1, NTRK2, NTRK3, and the nerve growth factor receptor (NGFR) (reviewed in Chao, 2003; Reichardt, 2006) . Although all four neurotrophins bind to NGFR with similar affinities (Chao, 2003; Reichardt, 2006) , and their pro-protein forms have been shown to bind to this receptor as well (Lee et al., 2001) , they are more selective in binding the NTRKs. NGF binds to NTRK1, BDNF and NTF4 to NTRK2, and NTF3 to NTRK3, each with high affinity (reviewed in Chao, 2003) . Another lesser known neurotrophin co-receptor, sortilin (SORT1), has been shown to interact with pro-neurotrophins in the brain and to control their release (reviewed in Nykjaer and Willnow 2012) . SORT1 is also involved in intracellular trafficking, directing proteins to various fates: cell surface expression, secretion, endocytosis or transport within the cell (reviewed in Nykjaer and Willnow, 2012) .
The interaction between BDNF and NTRK2 is not only capable of inducing neuronal development, differentiation, growth and maintenance, activation of the BDNF-NTRK2 pathway also induces angiogenesis , Nakamura et al. 2006 , proliferation (Tervonen et al., 2006; Kawamura et al., 2010) , adhesion (Zhou et al., 1997; Douma et al., 2004; Geiger and Peeper, 2007) and resistance to apoptosis (Douma et al. 2004 , Wang et al. 2005 , Geiger and Peeper, 2007 Kawamura et al., 2010; Li et al., 2011) . Each of these pathways is inextricably linked to reproduction, but the mechanisms regulating the uterine expression of neurotrophins remain unknown.
Both estrogen (Singh et al., 1995; Gibbs, 1998 , 1999 , Jezierski and Sohrabji, 2000 Berchtold et al., 2001; Liu et al., 2001; Solum and Handa, 2002; Scharfman and Maclusky, 2005; Pan et al., 2010; Tang and Wade, 2012) and progesterone (Kaur et al., 2007; Jodhka et al., 2009; Meyer et al., 2012; Su et al., 2012; Atif et al., 2013) regulate BDNF and its receptors in the brain, and we propose that their uterine regulation occurs in a similar manner. The aims of this study are to determine whether uterine BDNF, NTRK2, NGFR and SORT1 are affected by: (i) the acute, naturally occurring hormone fluctuations of the estrous cycle, and (ii) daily exposure to the ovarian hormones in ovariectomized mice. Here, we contrast the relatively stable expression of BDNF and its receptors over the estrous cycle with the significant up-regulation of uterine BDNF and its low affinity receptor NGFR in response to prolonged exposure to estradiol. Additionally, we document for the first time the presence of NGFR and SORT1 in the uterus.
Materials and Methods

Ethical approval
All procedures were approved by the animal research ethics board, McMaster University, Hamilton, ON, Canada (AUP 12-04-13).
Mice
Sexually mature female C57BL/6 mice (n ¼ 80) were purchased at 8 weeks of age from Charles River, and housed in a specific pathogen-free facility with a 12 h light/dark cycle, standard rodent chow, and water ad libitum.
Cycling mice
Mice (n ¼ 50) were randomly selected for estrous cycle monitoring. Animals were acclimated to vaginal lavage using sterile saline and a curved eyedropper for a 2-week period. Lavage was dried on a glass slide, and stained with a rapid Giemsa (Sigma-Aldrich, Oakville, ON, Canada) protocol. Briefly, slides were fixed in methanol for 5 min, air dried, and stained with Giemsa for 5 min. Estrous cycle stage was assessed on a daily basis by vaginal cytology (Wood et al., 2007; Caligioni, 2009; Byers et al., 2012) . Animals were euthanized at each stage of the estrous cycle (pro-estrus n ¼ 8; estrus n ¼ 18; metestrus n ¼ 9; diestrus n ¼ 15) by anesthetic overdose (isoflurane, Pharmaceutical Partners of Canada, Inc., Richmond Hill, ON, Canada). Uterine horns were immediately removed and stored at 2808C.
Ovariectomy and hormone replacement
In the second experiment, sexually mature female mice (n ¼ 30) were ovariectomized, and allowed to recover for 2 weeks. Mice were randomly assigned to treatment groups as outlined in Fig. 1 , using previously established methods and doses (Domino and Hurd, 2004; Gillgrass et al., 2005; Salgado et al., 2009 Salgado et al., , 2011 . All groups except the OVX group were primed for 3 days with 5 mg of 17-b estradiol (EMD Millipore, Billerica, MA, USA) by subcutaneous injection. After 2 days of rest, animals were given 5 mg of estradiol, 500 mg of progesterone, 5 mg of estradiol plus 500 mg of progesterone (EMD Millipore), or saline by subcutaneous injection for 4 days. Animals were euthanized, and uterine horns were collected as described above.
RNA and protein extraction
RNA and protein were extracted simultaneously from one uterine horn using the RNA/Protein Purification Plus kit (Norgen Biotek Corp., Thorold, ON, Canada) . Approximately 30 mg of uterine horn was cut and sonicated in 300 ml lysis buffer on ice for 30 s, three times. RNA was extracted following the manufacturer's protocol and quantified by Nanodrop (Thermo Scientific, Wilmington, DE, USA). cDNA was prepared using the iScript cDNA Synthesis Kit (Bio-Rad, Mississauga, ON, Canada). Protein concentration was determined by Bio-Rad Protein Assay (Bio-Rad).
Real-time PCR
Real-time PCR primers (Table I) were designed against the coding region of genes (to capture all isoforms) using sequences from NCBI Nucleotide, and Primer3 software (http://biotools.umassmed.edu/bioapps/primer3_ www.cgi). Primers were purchased from IDT Technologies (Coralville, IA, USA). PCR product was sequenced (Laboratory Services, University of Guelph, Guelph, ON, Canada), and BLASTed to confirm its identity. Sequences were submitted to NCBI's GenBank and are listed in Table I . Plate-based real-time PCR was performed in duplicate (958C 5 min, denaturation: 958C 10 s; annealing: see Table I 20 s; elongation: 728C 15 s; melting curve: 65 -97 2.58C/s) using the Roche LightCycler 480 (Roche Diagnostics, Laval, QC, Canada) and the SYBR Green I Master Mix (Roche). Relative quantification was performed with Gapdh as a reference gene using the Roche LightCycler software, which calculates an efficiency corrected normalized ratio of target gene to Gapdh using a mathematical algorithm developed by Roche. Bar graphs represent the group mean plus standard error of measurement (SEM).
For real-time PCR, Gapdh was used as a reference gene. Before relative quantification, a one-way ANOVA was used to determine if significant differences existed in crossing points between groups. No significant differences in Gapdh were observed between estrous cycle phases (P ¼ 0.179) nor between groups of the mice receiving hormone supplementation (P ¼ 0.271, data not shown).
Western blot
Total uterine protein (20 mg) was run on a 4 -20% gradient gel (Thermo Scientific, Burlington, ON, Canada) under reducing conditions at 150 V for 50 min, and transferred to PVDF (VWR International, Mississauga, ON, Canada) at 40 V for 90 min. Skim milk/TBS-T (5%) was used to block for 1 h at room temperature. Blots were incubated with primary antibody (Table II) overnight at 48C. Anti-Rabbit-ECL secondary (GE, Mississauga, ON, Canada) was applied for 1 h at 1:5000; then blots were incubated with enhanced chemiluminescence (ECL) substrate (Thermo-Scientific) for 5 min. X-ray film (Thermo-Scientific) was used for imaging; exposure times are listed in Table II . Blots were stripped using Restore Western Blot stripping buffer (Thermo-Scientific), and rinsed in TBS prior to incubation with another primary antibody. Densitometry was performed using ImageJ software (National Institutes of Health, Bethesda, MD, USA). b-Tubulin was employed as Uterine regulation of BDNF and its receptors the reference gene for the western blots. No differences in b-tubulin were observed in cycling mice (P ¼ 0.086) nor in ovariectomized mice receiving hormone supplementations (P ¼ 0.327, data not shown).
Immunohistochemistry
One uterine horn was fixed in 10% formaldehyde, processed, and embedded in paraffin. Uterine cross sections were cut at 4 mm, deparaffinized, and stained for BDNF (ab9794, Abcam, Cambridge, MA, USA, 1:200), NTRK2 (ab56652, Abcam, 1:200), NGFR (ab8874, Abcam, 1:100), and SORT1 (ab16640, Abcam, 1:500) using 1% BSA in PBS as a diluent. In lieu of primary antibody, negative sections were incubated with the blocking solution in the Rabbit Vectastain ABC kit (Vector Labs, Burlington, ON, Canada). The ABC kit was used as per manufacturer's protocol, and DAB was employed as a chromogen (including negative sections). Images were captured with an Infinity camera (Lumenera Corp., Ottawa, ON, Canada) and Olympus IX81 microscope (Olympus, Richmond Hill, ON, Canada).
Quantification of NGFR staining
Four random images of uterine cross sections per mouse were obtained from mice in all cycle phases and treatment groups (n ¼ 3 per phase or group). Luminal epithelial, glandular epithelial and stromal cells were counted (100 cells per type) and the percent staining positive for NGFR was calculated.
Data and statistical analysis
Within our data, there were values non-detectable by real-time PCR or western blot. There are several methods to handle non-detectable data points including: assigning these data a value of 0, the limit of detection for the assay, the square root of the limit of detection, or a random number between the limit of detection and zero (Newton and Rudel, 2007; Fievet and Della Vedova, 2010; Ballenberger et al., 2012; Boyer et al., 2013) . We assigned a random number between the limit of detection for the gene or protein of interest and zero using the random number generator in the SigmaStat software package (SigmaStat 3.5 Systat Software, Inc., Chicago, IL, USA) because this method will randomly skew the data toward or away from zero, rather than always skewing it in the same direction. Statistical outliers in the data were identified by Grubb's test (http://graphpad.com/quickcalcs/ Grubbs1.cfm) for N . 6, and the Dixon's Q test for a single outlier, for smaller sample sizes (http://contchart.com/outliers.aspx). Outliers were removed prior to analysis. Any other sample omissions were due to technical error. The number of non-detects, outliers, and omissions are in Supplementary Fig. S1 . Real-time PCR and western blot data were compared by one-way ANOVA (SigmaStat 3.5 Systat Software, Inc., Chicago, IL, USA) and Tukey post hoc test. Data that were not normally distributed were analyzed by ANOVA on rank's and Dunn's post hoc test performed. A P-value of ,0.05 was considered significant. Bars on the graphs represent the mean plus the standard error of measurement (SEM). Uterine localization of NGFR was compared by t-test.
Results
BDNF expression in the cycling mouse uterus
Bdnf transcripts were decreased (P ¼ 0.031) in metestrus compared with estrus ( Fig. 2A) . When BDNF expression was assessed by western blot, four bands ( 25, 27, 37, and 40 kDa) were observed in 37 of 39 uteri ( Fig. 2B and D) . No differences in the 25, 27, 37 or 40 kDa BDNF bands (P ¼ 0.425, 0.263, 0.137, 0.107 respectively; Fig. 2B and D) were observed over the estrous cycle.
BDNF receptor expression in the cycling mouse uterus
Ntrk2 transcripts were elevated in diestrus compared with metestrus (P ¼ 0.017; Fig. 2A ). NTRK2 55 kDa protein ( Fig. 2B and D) , an isoform we previously demonstrated in the human uterus and mouse brain using another NTRK2 antibody (Wessels et al., 2014) , remained stable over the estrous cycle (P ¼ 0.691). The long (140 kDa) and truncated (95 kDa) forms of NTRK2 were below the limit of detection, even after an hour exposure. Ngfr transcripts were unaltered across the estrous cycle (P ¼ 0.221; Fig. 2A ). However NGFR protein decreased over the estrous cycle with levels at diestrus being significantly lower (P ¼ 0.005) than those at pro-estrus or estrus (Fig. 2B -D) . Transcripts and protein for SORT1 were unaffected by estrous cycle stage (P ¼ 0.104, P ¼ 0.130; Fig. 2A , B and D).
Uterine localization of BDNF and its receptors in the cycling mouse uterus BDNF and NTRK2 were co-localized in the luminal epithelium, glandular epithelium, stroma and smooth muscle in the cycling mouse uterus (representative images, Fig. 3 ). NGFR was also present in all uterine cell types ( Figs 3 and 4) , but its expression in the luminal epithelium was dependent on whether there was a dominance of estrogen (pro-estrus, estrus, metestrus) or progesterone (diestrus) (Fig. 4A and B) . NGFR expression increased (P , 0.001) in the luminal epithelium at diestrus when compared with other cycle stages (Fig. 4A) . NGFR expression was absent in the internal layer of smooth muscle in the myometrium, but present in the external layer (Fig. 3) . SORT1 remained consistently expressed in the luminal and glandular epithelium (Fig. 3) .
Hormonal regulation of BDNF in the mouse uterus
Estrogen and progesterone increased Bdnf transcripts above ovariectomized controls, estrogen treated, and progesterone treated alone (P ¼ 0.002; Fig. 5A ). Treatment with estradiol significantly increased all quantified isoforms of BDNF in the mouse uterus ( Fig. 5B-D) . The 25 kDa band increased 6-fold above estrogen primed mice given saline (P ¼ 0.013), and the 27 kDa band increased .7-fold (P ¼ 0.003) above those given saline or progesterone. Estrogen treatment also significantly increased (P ¼ 0.041) the 37 kDa form of BDNF above mice receiving saline. Additionally, estrogen treatment enhanced the 40 kDa band (P ¼ 0.046) when compared with those treated with progesterone only. 
Hormonal regulation of BDNF receptors in the mouse uterus
No significant change in uterine Ntrk2 transcripts was identified (P ¼ 0.066, Fig. 5A ). The 55 kDa band was not changed by hormonal treatment (P ¼ 0.788; Fig. 5B and D) . The full-length (140 kDa) and truncated (95 kDa) NTRK2 receptors were not quantifiable by western blot, after a 1 h exposure. No differences in Ngfr transcripts in the uterus were observed in the ovariectomized mice supplemented with exogenous Sort1 (n ¼ 8, 18, 9, 15) transcripts using Gapdh as a reference gene (A). Densitometry values for BDNF (n ¼ 8, 11, 9, 10), NTRK2 (n ¼ 7, 12, 9, 10), NGFR (n ¼ 7, 12, 8, 9) and SORT1 (n ¼ 8, 12, 9, 10), expressed as a % loading control using b-tubulin (B). Graph of the statistically significant differences in NGFR expression over the estrous cycle (C). Representative western blot images showing immunoreactive bands for BDNF, NTRK2, NGFR, SORT1 and b-tubulin which was used as the reference gene for densitometry (D). Data are presented as mean + standard error. Statistically significant differences are denoted by an asterisk (*) above the graph, or by different superscripts in the table (B). Outliers were not included in statistical analysis, but are denoted by a dot on the graph if they fell within its range. E: estrus, D: diestrus, M: metestrus, P: pro-estrus.
hormones (P ¼ 0.131; Fig. 5A ). NGFR expression in the uterus was significantly increased (P , 0.001) by estradiol treatment when compared with saline and P4 treated animals ( Fig. 5B -D) . Estrogen and progesterone co-treatment increased Sort1 transcripts in the uterus above mice treated with estrogen alone, or saline (P ¼ 0.007; Fig. 5A ). This difference in SORT1 was not observed at the protein level (P ¼ 0.503; Fig. 5B and D) .
Uterine localization of BDNF and its receptors in the hormone replacement mouse uterus BDNF and NTRK2 were located in the luminal epithelium, glandular epithelium, stroma and smooth muscle in the mouse uterus of all treatment groups (representative images from mice treated with estradiol in Fig. 6 ). Mice treated with estradiol had enhanced BDNF expression, particularly in stromal cells. NGFR was found in all uterine cell types (Figs 4 and 6 ) but, as in cycling mice, its localization was dependent on whether mice were exposed to estrogen or progesterone (representative images from mice treated with estradiol in Fig. 6 ). NGFR expression was increased in the stromal cells of ovariectomized mice given estrogen (P ¼ 0.002) when compared with mice given progesterone or the ovariectomized controls (group O), and its expression switched to the luminal (P , 0.001) and glandular epithelium (P ≤ 0.001) in mice given progesterone (Fig. 4C) . SORT1 was located on the apical side of the glandular epithelium, and occasionally, the luminal epithelium (representative images from mice treated with progesterone in Fig. 6 ).
Discussion
Emerging evidence suggests an important role for BDNF in uterine physiology and pathology. Herein we show that BDNF and its low affinity receptor NGFR are regulated by estradiol in the uterus. We contrast the expression of uterine BDNF and its receptors during the 4-day estrous cycle with expression in response to daily estradiol exposure during hormone replacement, as summarized in Fig. 7 .
Estrogen regulates BDNF expression in the uterus
In ovariectomized mice, daily estrogen significantly increased all of the BDNF isoforms quantified. BDNF can be a monomer (13 kDa), dimer (26 kDa), or pro-(42 kDa) protein, and can undergo post-translational modifications (Mowla et al., 2001; Teng et al., 2005; Pruunsild et al., 2007; Matsumoto et al., 2008; Koshimizu et al., 2009) . Stability studies suggest BDNF dimers are stable, even under reducing blot conditions (Radziejewski et al., 1992; Kolbeck et al., 1994; Pan et al., 1998) . Thus, the 25, 27, 37 and 40 kDa bands are likely dimerized and pro-BDNF, with and without post-translational modification. Although progesterone affects BDNF expression in the brain (Kaur et al., 2007; Jodhka et al., 2009; Meyer et al., 2012; Su et al., 2012; Atif et al., 2013) and nervous system (Gonzalez et al., 2004 (Gonzalez et al., , 2005 De Nicola et al., 2006; Gonzalez Deniselle et al., 2007; Cekic et al., 2012) , and BDNF is expressed in luteinized granulosa cells (Dominguez et al., 2011) , progesterone did not alter uterine BDNF. Our results concur with Coughlan et al. (2009) where progesterone did not alter BDNF expression in response to neuronal injury. As Jodhka et al. (2009) reported that progesterone was capable of increasing BDNF in the brain but medroxyprogesterone was not, we speculate that the form of progesterone employed affects induction of BDNF. While this is the first report of estrogen-induced BDNF expression in the uterus, previous studies in the brain support a role for estrogen in BDNF regulation (Toran-Allerand et al., 1992; Miranda et al., 1993; Singh et al., 1995; Sohrabji et al., 1995; Gibbs, 1998 Gibbs, , 1999 Sohrabji, 2000, 2001; Berchtold et al., 2001; Liu et al., 2001; Solum and Handa, 2002; Scharfman and Maclusky, 2005; Pan et al., 2010; Tang and Wade, 2012) . Additionally, circulating levels of BDNF strongly BDNF, and NTRK2 were co-localized in the luminal epithelium, glandular epithelium, stroma, and smooth muscle in the cycling mouse uterus. Expression of NGFR was also present in all uterine cell types but its localization was dependent on whether there was a dominance of estrogen (pro-estrus) or progesterone (diestrus) (see Fig. 4 ). SORT1 remained consistently expressed in the luminal and glandular epithelium. Inset images: negative control sections incubated with blocking serum in lieu of primary antibody. Original magnification: ×200, ×400. Scale bar ¼ 50 mm. n ¼ 8 (pro-estrus), 18 (estrus), 9 (metestrus), 15 (diestrus). GE: glandular epithelium, LE: luminal epithelium, S: stroma, SM: smooth muscle. E: estrus, D: diestrus, M: metestrus, P: pro-estrus.
correlate with estradiol (Pluchino et al., 2009) , and fluctuate over the menstrual cycle in women (Begliuomini et al., 2007) , and BDNF can be induced by estrogen in the rat uterus (Krizsan-Agbas et al., 2003) .
Here we have shown that daily estrogen exposure after ovariectomy significantly increases uterine BDNF, but the hormonal fluctuations of the murine estrous cycle do not. Figure 4 NGFR localization in response to estrogen versus progesterone. In cycling mice, NGFR expression was increased in the luminal epithelium at diestrus (P , 0.001) compared with the other cycle phases (A, B) . In ovariectomized mice, the administration of estradiol increased NGFR expression in the stromal cells (P , 0.001) when compared with animals given progesterone. The pattern of expression switched to the luminal (P , 0.001) and glandular epithelium (P ¼ 0.002) when mice were given progesterone (C, D). Data are presented as mean + standard error. Statistically significant differences are denoted by different superscripts above the bars. Inset images: negative control sections incubated with blocking serum in lieu of primary antibody. Original magnification: ×200. Scale bar ¼ 50 mm. n ¼ 3 per group. E: estrus, D: diestrus, M: metestrus, P: pro-estrus. GE: glandular epithelium, LE: luminal epithelium, S: stroma, SM: smooth muscle. O, S, E2, P4, E2/P4: treatment groups according to Fig. 1 . N.S.: not statistically significant. Figure 5 Hormonal regulation of BDNF and its receptors in the mouse uterus. Ovariectomized mice were assigned to treatment groups as outlined in Fig. 1 . Quantification of Bdnf (n ¼ 5, 6, 6, 5, 6), Ntrk2 (n ¼ 5, 5, 5, 6, 5), Ngfr (n ¼ 5, 6, 6, 6, 6) and Sort1 (n ¼ 4, 6, 6, 6, 6 ) transcripts using Gapdh as a reference gene (A). Densitometry values for BDNF (n ¼ 5, 6, 6, 6, 6), NTRK2 (n ¼ 5, 5, 6, 6, 6), NGFR (n ¼ 4, 6, 6, 5, 6) and SORT1 (n ¼ 5, 6, 6, 6, 6) , expressed as a % loading control using b-tubulin (B). Graph of the statistically significant differences in BDNF and NGFR expression in response to exogenous hormones (C). Representative western blot images showing immunoreactive bands for BDNF, NTRK2, NGFR, SORT1 and b-tubulin which was used as the reference gene for densitometry. Each gene quantified by densitometry was run on the same membrane; the images have been cropped to reflect the experimental groupings in the graphs (D). Data are presented as mean + standard error. Statistically significant differences are denoted by an asterisk (*) above the graph, or by different superscripts in the table (B). Outliers were not included in statistical analysis, but are denoted by a dot on the graph if they fell within its range. O, S, E2, P4, E2/P4: treatment groups according to Fig. 1 . OVX: ovariectomy.
Estrogen regulates BDNF receptors in the uterus
The uterine expression of NGFR decreased over the estrous cycle, and increased in response to estrogen supplementation, while no hormonal regulation of NTRK2 or SORT1 was observed. We postulate that estrogen stabilizes NGFR or increases its half-life, as Ngfr transcripts are not affected by estradiol. Alternately, estrogen may enhance translation of transcripts, without increasing their quantity (signal amplification). The precise mechanism of estradiol action is unclear, but is likely via indirect regulation of the NGFR protein. Further, NGFR was spatially regulated in the uterus; expression shifted from stromal to epithelial cells when ovariectomized animals were given estrogen versus progesterone.
Regulation of BDNF receptors by estradiol and progesterone in the brain, nervous system (Gibbs and Pfaff, 1992; Sohrabji et al., 1994a,b; Jezierski and Sohrabji, 2001; Brito et al., 2004; Hasan et al., 2005; De Nicola et al., 2006; Spencer et al., 2008; Anesetti et al., 2009; Pan et al., 2010; Cekic et al., 2012; Tang and Wade, 2012) and ovary (Lara et al., 2000) have been reported. Interestingly, in Hasan et al. (2005) , acute estrogen exposure in sympathetic neurons did not affect NGFR expression, but chronic exposure did. Here we have shown that uterine NGFR expression decreases over the estrous cycle, and increases in response to daily estrogen exposure after ovariectomy, while other BDNF receptors remain stable. We have also demonstrated the spatial regulation of NGFR in response to ovarian hormones.
BDNF and receptor expression in ovary intact cycling mice when compared with ovariectomized and estradiol replaced mice In mice, the estrous cycle likely occurs too quickly to significantly affect uterine neurotrophins. Although transcripts for Bdnf and Ntrk2 varied over the estrous cycle, BDNF, NTRK2, and SORT1 expression remained stable and NGFR declined from pro-estrus through diestrus. This decline would increase the local bioavailability of BDNF and signaling through the BDNF-NTRK2 pathways in the uterus during the latter part of the cycle. Thus, under physiological conditions the neurotrophic milieu of the uterus is controlled by NGFR. However, when mice were exposed to daily high dose estrogen, which models the chronic estrogen present in endometriotic lesions in women with endometriosis (Noble et al., 1996; Huhtinen et al., 2012) or other estrogen-dependent diseases, the exposure had profoundly different effects on the uterine expression of BDNF and its receptors. Estradiol treatment significantly increased the uterine expression of mature BDNF (.6-fold), pro-BDNF (.5-fold) and NGFR (5-fold) when compared with the other treatments. While neither NTRK2 nor SORT1 were affected by ovarian hormones, continued daily exposure to estradiol increased mature BDNF which would lead to the induction of the BDNF-NTRK2 pathways, without affecting NTRK2 levels.
The neurotrophins are a complex network, and regulation of BDNF and NGFR by estrogen in the uterus can impact many BDNF pathways including angiogenesis Nakamura et al., 2006) , cellular proliferation (Tervonen et al., 2006; Kawamura et al., 2010) , adhesion (Zhou et al., 1997; Douma et al., 2004; Geiger and Peeper, 2007) and resistance to apoptosis (Douma et al., 2004; Wang et al., 2005; Geiger and Peeper, 2007; Kawamura et al., 2010; Li et al., 2011) . Here, we also demonstrated the effect of estrogen on pro-BDNF in the uterus. The precise function of each BDNF isoform is only beginning to be elucidated, but generally pro-BDNF counteracts the effects of mature BDNF, providing another level of regulation for the powerful pathways activated by BDNF. We have shown a temporal effect to the hormonal regulation of NGFR in the cycling uterus, and highlighted the Figure 6 BDNF and receptor localization in the hormone replacement mouse uterus. Uterine localization of BDNF and its receptors in ovariectomized mice given hormone supplementation according to Fig. 1 . BDNF, and NTRK2 were located in the luminal epithelium, glandular epithelium, stroma, and smooth muscle in the mouse uterus of all treatment groups (representative images from mice treated with estradiol). NGFR was found in all uterine cell types, but as in the cycling mice its localization was dependent on whether mice were exposed to estrogen or progesterone (see Fig. 4 ) (representative images from mice treated with estradiol). SORT1 was located on the apical side of the glandular epithelium, and the luminal epithelium in the uteri of mice in all treatment groups (representative images from mice treated with progesterone). Inset images: negative control sections incubated with blocking serum in lieu of primary antibody. Original magnification: ×200, ×400. Scale bar ¼ 50 mm. GE: glandular epithelium, LE: luminal epithelium, S: stroma, SM: smooth muscle. differential spatial localization of NGFR in response to ovarian hormones. The neurotrophins are involved in reproductive pathologies (Borghese et al., 2010; Browne et al., 2012; Bao et al., 2013; Barcena de Arellano et al., 2013) , and physiological processes (Kawamura et al., 2009 (Kawamura et al., , 2011 Kerr et al., 2009; Dorfman et al., 2011 Dorfman et al., , 2014 Shoae-Hassani et al., 2011; Non et al., 2012) . Although little is known about the functions of BDNF and its receptors within the reproductive system, they are poised to participate in many aspects of reproductive physiology and pathology. The results of this study implicate estrogen in the uterine up-regulation of BDNF and NGFR, and highlight the differing effect of hormone exposure during the estrous cycle versus estradiol replacement after ovariectomy on neurotrophin expression. Sustained estrogen exposure, as seen in estrogen-dependent disease, may tip the neurotrophin balance and inappropriately activate pathways important in the disease pathophysiology.
Supplementary data
Supplementary data are available at http://humrep.oxfordjournals.org/.
Figure 7
Contrasting uterine BDNF and receptor expression in cycling mice versus ovariectomy + estradiol replacement. A summary of the uterine expression of BDNF, NTRK2, NGFR and SORT1 in the uterus under physiological conditions (hormone exposure during the estrous cycle) when compared with mice undergoing daily estradiol replacement according to the regimen in Fig. 1 (E2 group). Green arrow: NGFR significantly decreases over the estrous cycle, under physiological conditions. Red arrow: BDNF and NGFR are significantly increased by daily estrogen exposure in ovariectomized mice. Yellow arrow: no change over the estrous cycle or treatment groups.
